Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses.
Availability of an individualized preselection of oncolytic viruses to be used for virotherapy of tumor patients would be of great help. Using primary liver tumor resection specimens we evaluated the precision-cut liver slice (PCLS) technology as a novel in vitro test system for characterization of paramount tumor infection parameters of individual patients. PCLS slices from resection specimens of 20 liver tumor patients were cultivated in vitro for up to 5 days and infected with 5 different oncolytic measles vaccine virus (MeV) strains. Effectiveness of tumor infection was monitored by viral nucleocapsid (N) protein detection in immunofluorescence staining or Western blot analysis or by detection of GFP marker gene expression. MeV spreading in PCLS cultures was visualized by confocal microscopy. Oncolytic MeV vaccine particles were demonstrated to efficiently infect PCLS slices originating from different primary and secondary tumors of the liver with MeV strains Moraten/Edmonston Zagreb and AIK-C showing highest infection rates (75% of all tested tumor specimens). Employing mixed liver tissue slices (exhibiting both tumorous and non-tumorous tissue areas on one and the same sample) a distinct tumor area favouring pattern of MeV infections was observed being in accordance with our finding that primary human hepatocytes are also permissive to MeV particles, albeit at a much lower rate and with a much less pronounced cytopathic effect. Furthermore, confocal microscopy demonstrated virus penetration throughout tumor tissues into deep cell layers. In conclusion, the PCLS technology is suitable to perform a tumor-patient individualized preselection of oncolytic agents prior to clinical virotherapeutic applications.
Zimmermann
Martina
M
Department of Gastroenterology and Hepatology, Medical University Hospital, D-72076 Tübingen, Germany.
Armeanu
Sorin
S
Smirnow
Irina
I
Kupka
Susan
S
Wagner
Silvia
S
Wehrmann
Manfred
M
Rots
Marianne G
MG
Groothuis
Geny M M
GM
Weiss
Thomas S
TS
Königsrainer
Alfred
A
Gregor
Michael
M
Bitzer
Michael
M
Lauer
Ulrich M
UM
D000818:Animals; D001706:Biopsy / Q000379:methods; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D019073:HT29 Cells; D006801:Humans; D007206:Individuality; D008099:Liver / Q000473:pathology* / Q000821:virology; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008457:Measles / Q000473:pathology / Q000821:virology; D008458:Measles Vaccine / Q000627:therapeutic use*; D042282:Microdissection / Q000379:methods*; D050130:Oncolytic Virotherapy; D011379:Prognosis; D014709:Vero Cells
D008458:Measles Vaccine